{"transactions":[{"id":712676,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":31451,"kind":"person","name":"Carter Charles Ross","position":1,"cik":"0001779359","reported_name":"Carter Charles Ross","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-08T20:31:44.000Z","date":"2026-07-06","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest in two equal annual installments commencing on July 6, 2027, subject to the Reporting Person's continuous service through each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":94375,"source":{"system":"sec-edgar","filing":"0001779359-26-000004","document":"form4-07082026_080741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779359/000177935926000004/form4-07082026_080741.xml","form_type":"4"}},{"id":733337,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":37126,"kind":"person","name":"Greka Anna","position":1,"cik":"0002138163","reported_name":"Greka Anna","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-17T20:22:24.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option will vest in 36 equal monthly installments commencing on July 15, 2026, subject to the Reporting Person's continued services through each such date."}],"balance_after":130000,"derivative":{"exercise_price":2.26,"expiration_date":"2036-06-14","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0002138163-26-000005","document":"form4-06172026_080618.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000213816326000005/form4-06172026_080618.xml","form_type":"4"}},{"id":811374,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:15:09.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":17578,"price":2.56,"value":44999.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000.  The RSUs  vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":217578,"source":{"system":"sec-edgar","filing":"0001202098-26-000004","document":"form4-04092026_050404.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120209826000004/form4-04092026_050404.xml","form_type":"4"}},{"id":811330,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53061,"kind":"person","name":"Friedman Bart","position":1,"cik":"0001368324","reported_name":"Friedman Bart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:15:07.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":8789,"price":2.56,"value":22499.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of 50% of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $22,500. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":8789,"source":{"system":"sec-edgar","filing":"0001368324-26-000004","document":"form4-04092026_050403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368324/000136832426000004/form4-04092026_050403.xml","form_type":"4"}},{"id":811641,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-09T21:15:06.000Z","date":"2026-04-07","kind":"grant","planned":false,"acquired":true,"shares":17578,"price":2.56,"value":44999.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":17578,"source":{"system":"sec-edgar","filing":"0001886431-26-000004","document":"form4-04092026_050401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886431/000188643126000004/form4-04092026_050401.xml","form_type":"4"}},{"id":828139,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series A Warrant (right to buy)","published_at":"2026-03-26T01:18:27.000Z","date":"2026-03-23","kind":"exercise","planned":false,"acquired":false,"shares":47333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Series A Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025."}],"balance_after":0,"derivative":{"exercise_price":1.4,"expiration_date":"2026-04-17","underlying":"Common Stock","underlying_shares":47333},"source":{"system":"sec-edgar","filing":"0001256153-26-000004","document":"form4-03262026_010323.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000125615326000004/form4-03262026_010323.xml","form_type":"4"}},{"id":828138,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2026-03-26T01:18:27.000Z","date":"2026-03-23","kind":"exercise","planned":false,"acquired":true,"shares":47333,"price":1.4,"value":66266.2,"ownership":{"direct":true},"balance_after":3735048,"source":{"system":"sec-edgar","filing":"0001256153-26-000004","document":"form4-03262026_010323.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000125615326000004/form4-03262026_010323.xml","form_type":"4"}},{"id":873742,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-02T21:30:20.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":1.65,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001202098-26-000002","document":"form4-03022026_040315.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000120209826000002/form4-03022026_040315.xml","form_type":"4"}},{"id":874608,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-02T21:30:17.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":1.65,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001886431-26-000002","document":"form4-03022026_040313.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886431/000188643126000002/form4-03022026_040313.xml","form_type":"4"}},{"id":873719,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-02T21:30:17.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":957000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date."}],"balance_after":957000,"derivative":{"exercise_price":1.65,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":957000},"source":{"system":"sec-edgar","filing":"0001256153-26-000002","document":"form4-03022026_040301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000125615326000002/form4-03022026_040301.xml","form_type":"4"}},{"id":873680,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53061,"kind":"person","name":"Friedman Bart","position":1,"cik":"0001368324","reported_name":"Friedman Bart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-02T21:30:16.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":1.65,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001368324-26-000002","document":"form4-03022026_040311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368324/000136832426000002/form4-03022026_040311.xml","form_type":"4"}},{"id":873847,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"DUNCAN BARBARA GAYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-02T21:30:14.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":1.65,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001353128-26-000002","document":"form4-03022026_040309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000135312826000002/form4-03022026_040309.xml","form_type":"4"}},{"id":873493,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63872,"kind":"person","name":"Bernstein Karen","position":1,"cik":"0001654055","reported_name":"Bernstein Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-02T21:30:11.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":1.65,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001654055-26-000002","document":"form4-03022026_040307.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000165405526000002/form4-03022026_040307.xml","form_type":"4"}},{"id":873704,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-02T21:30:09.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":408750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date."}],"balance_after":408750,"derivative":{"exercise_price":1.65,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":408750},"source":{"system":"sec-edgar","filing":"0001311404-26-000002","document":"form4-03022026_040305.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000131140426000002/form4-03022026_040305.xml","form_type":"4"}},{"id":873703,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Common Stock","published_at":"2026-03-02T21:30:09.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":68125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest in three equal annual installments commencing on February 20, 2027, subject to the Reporting Person's continuous service through each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":156313,"source":{"system":"sec-edgar","filing":"0001311404-26-000002","document":"form4-03022026_040305.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000131140426000002/form4-03022026_040305.xml","form_type":"4"}},{"id":873702,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Common Stock","published_at":"2026-03-02T21:30:09.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":8541,"price":1.45,"value":12384.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 28,756 shares acquired under the Issuer's employee stock purchase plan."}],"balance_after":88188,"source":{"system":"sec-edgar","filing":"0001311404-26-000002","document":"form4-03022026_040305.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000131140426000002/form4-03022026_040305.xml","form_type":"4"}},{"id":874764,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":64010,"kind":"person","name":"ALEXANDER MARGARET A.","position":1,"cik":"0002036798","reported_name":"ALEXANDER MARGARET A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-02T16:30:24.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":1435000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date."}],"balance_after":1435000,"derivative":{"exercise_price":1.65,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":1435000},"source":{"system":"sec-edgar","filing":"0002036798-26-000004","document":"form4-03022026_040303.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036798/000203679826000004/form4-03022026_040303.xml","form_type":"4"}},{"id":874763,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":64010,"kind":"person","name":"ALEXANDER MARGARET A.","position":1,"cik":"0002036798","reported_name":"ALEXANDER MARGARET A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-02T16:30:24.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":11656,"price":1.45,"value":16901.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":61750,"source":{"system":"sec-edgar","filing":"0002036798-26-000004","document":"form4-03022026_040303.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036798/000203679826000004/form4-03022026_040303.xml","form_type":"4"}},{"id":952302,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":64010,"kind":"person","name":"ALEXANDER MARGARET A.","position":1,"cik":"0002036798","reported_name":"ALEXANDER MARGARET A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-05T17:55:06.000Z","date":"2026-01-04","kind":"grant","planned":false,"acquired":true,"shares":890000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on January 1, 2027 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date."}],"balance_after":890000,"derivative":{"exercise_price":1.76,"expiration_date":"2036-01-03","underlying":"Common Stock","underlying_shares":890000},"source":{"system":"sec-edgar","filing":"0002036798-26-000002","document":"form4-01052026_050101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036798/000203679826000002/form4-01052026_050101.xml","form_type":"4"}},{"id":962960,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-12-18T21:15:07.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":71,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":71000},"source":{"system":"sec-edgar","filing":"0001256153-25-000004","document":"form4-12182025_041203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000125615325000004/form4-12182025_041203.xml","form_type":"4"}},{"id":962959,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Series B Warrant (right to buy)","published_at":"2025-12-18T21:15:07.000Z","date":"2025-12-11","kind":"purchase","planned":false,"acquired":true,"shares":35500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 71 investment units purchased by the Reporting Person for $1,400 per investment unit. Each investment unit consists of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each Series B Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025."}],"balance_after":35500,"derivative":{"exercise_price":1.4,"expiration_date":"2030-10-06","underlying":"Common Stock","underlying_shares":35500},"source":{"system":"sec-edgar","filing":"0001256153-25-000004","document":"form4-12182025_041203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000125615325000004/form4-12182025_041203.xml","form_type":"4"}},{"id":962958,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Series A Warrant (right to buy)","published_at":"2025-12-18T21:15:07.000Z","date":"2025-12-11","kind":"purchase","planned":false,"acquired":true,"shares":47333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 71 investment units purchased by the Reporting Person for $1,400 per investment unit. Each investment unit consists of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Series A Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series A Warrants will terminate upon the earlier of (a) the 30th calendar day following date on which we publicly announce the clearance of the first of any investigational new drug application, clinical trial application or other foreign equivalent with respect to the clinical development of our OV4071 product candidate; provided that such 30-calendar day period shall not commence unless and until a registration statement covering the resale of the shares of Common Stock issuable upon exercise of the Series A Warrants is effective; and (b) October 6, 2030."}],"balance_after":47333,"derivative":{"exercise_price":1.4,"underlying":"Common Stock","underlying_shares":47333},"source":{"system":"sec-edgar","filing":"0001256153-25-000004","document":"form4-12182025_041203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000125615325000004/form4-12182025_041203.xml","form_type":"4"}},{"id":962957,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Series B Convertible Preferred Stock","published_at":"2025-12-18T21:15:07.000Z","date":"2025-12-11","kind":"purchase","planned":false,"acquired":true,"shares":71,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities are included within 71 investment units purchased by the Reporting Person for $1,400 per investment unit. Each investment unit consists of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025."}],"balance_after":71,"derivative":{"underlying":"Common Stock","underlying_shares":71000},"source":{"system":"sec-edgar","filing":"0001256153-25-000004","document":"form4-12182025_041203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000125615325000004/form4-12182025_041203.xml","form_type":"4"}},{"id":962956,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-12-18T21:15:07.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":71000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025."}],"balance_after":3687715,"source":{"system":"sec-edgar","filing":"0001256153-25-000004","document":"form4-12182025_041203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000125615325000004/form4-12182025_041203.xml","form_type":"4"}},{"id":976109,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":2,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-12-09T21:19:26.000Z","date":"2025-12-08","kind":"exercise","planned":false,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A convertible preferred stock (the \"Preferred Stock\") of Ovid Therapeutics Inc. (\"Ovid\") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001395064-25-000172","document":"wk-form4_1765333162.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716229/000139506425000172/wk-form4_1765333162.xml","form_type":"4"}},{"id":976108,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":2,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-09T21:19:26.000Z","date":"2025-12-08","kind":"exercise","planned":false,"acquired":true,"shares":1250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Series A convertible preferred stock (the \"Preferred Stock\") of Ovid Therapeutics Inc. (\"Ovid\") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA."}],"balance_after":7000000,"source":{"system":"sec-edgar","filing":"0001395064-25-000172","document":"wk-form4_1765333162.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716229/000139506425000172/wk-form4_1765333162.xml","form_type":"4"}},{"id":1106502,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T20:45:12.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":0.57,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-25-017698","document":"form4-06182025_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886431/000141588925017698/form4-06182025_040608.xml","form_type":"4"}},{"id":1106028,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53061,"kind":"person","name":"Friedman Bart","position":1,"cik":"0001368324","reported_name":"Friedman Bart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T20:45:09.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":0.57,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-25-017697","document":"form4-06182025_040606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368324/000141588925017697/form4-06182025_040606.xml","form_type":"4"}},{"id":1106133,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T20:45:07.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":0.57,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-25-017696","document":"form4-06182025_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000141588925017696/form4-06182025_040603.xml","form_type":"4"}},{"id":1105946,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63872,"kind":"person","name":"Bernstein Karen","position":1,"cik":"0001654055","reported_name":"Bernstein Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T20:45:05.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":0.57,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-25-017695","document":"form4-06182025_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000141588925017695/form4-06182025_040601.xml","form_type":"4"}},{"id":1227289,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":43288,"kind":"person","name":"PAPADOPOULOS STELIOS","position":1,"cik":"0001202098","reported_name":"PAPADOPOULOS STELIOS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-03-04T21:44:34.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option will vest in 36 equal monthly installments commencing on April 3, 2025, subject to the Reporting Person's continued services through each such date."}],"balance_after":90000,"derivative":{"exercise_price":0.49,"expiration_date":"2035-03-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001415889-25-006568","document":"form4-03042025_090327.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202098/000141588925006568/form4-03042025_090327.xml","form_type":"4"}},{"id":1238110,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Common Stock","published_at":"2025-02-28T21:15:08.000Z","date":"2025-02-26","kind":"sale","planned":false,"acquired":false,"shares":3902,"price":0.56,"value":2185.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."}],"balance_after":67973,"source":{"system":"sec-edgar","filing":"0001415889-25-005997","document":"form4-02282025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000141588925005997/form4-02282025_040201.xml","form_type":"4"}},{"id":1238885,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":64010,"kind":"person","name":"ALEXANDER MARGARET A.","position":1,"cik":"0002036798","reported_name":"ALEXANDER MARGARET A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2025-02-28T16:15:10.000Z","date":"2025-02-26","kind":"sale","planned":false,"acquired":false,"shares":5279,"price":0.56,"value":2956.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."}],"balance_after":73406,"source":{"system":"sec-edgar","filing":"0001415889-25-005998","document":"form4-02282025_040204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036798/000141588925005998/form4-02282025_040204.xml","form_type":"4"}},{"id":1249211,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-25T00:55:09.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":1650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2025, subject to the Reporting Person's continued services through each such date."}],"balance_after":1650000,"derivative":{"exercise_price":0.57,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":1650000},"source":{"system":"sec-edgar","filing":"0001415889-25-005368","document":"form4-02242025_070206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000141588925005368/form4-02242025_070206.xml","form_type":"4"}},{"id":1249202,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-25T00:55:07.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":262500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2025, subject to the Reporting Person's continued services through each such date."}],"balance_after":262500,"derivative":{"exercise_price":0.57,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":262500},"source":{"system":"sec-edgar","filing":"0001415889-25-005367","document":"form4-02242025_070203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000141588925005367/form4-02242025_070203.xml","form_type":"4"}},{"id":1249201,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Common Stock","published_at":"2025-02-25T00:55:07.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":43750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest in three equal annual installments commencing on February 22, 2026, subject to the Reporting Person's continuous service through each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":71875,"source":{"system":"sec-edgar","filing":"0001415889-25-005367","document":"form4-02242025_070203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000141588925005367/form4-02242025_070203.xml","form_type":"4"}},{"id":1250058,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":64010,"kind":"person","name":"ALEXANDER MARGARET A.","position":1,"cik":"0002036798","reported_name":"ALEXANDER MARGARET A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-02-24T19:55:05.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":262500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2025, subject to the Reporting Person's continued services through each such date."}],"balance_after":262500,"derivative":{"exercise_price":0.57,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":262500},"source":{"system":"sec-edgar","filing":"0001415889-25-005366","document":"form4-02242025_070201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2036798/000141588925005366/form4-02242025_070201.xml","form_type":"4"}},{"id":1250057,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":64010,"kind":"person","name":"ALEXANDER MARGARET A.","position":1,"cik":"0002036798","reported_name":"ALEXANDER MARGARET A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2025-02-24T19:55:05.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":43750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest in three equal annual installments commencing on February 22, 2026, subject to the Reporting Person's continuous service through each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":78685,"source":{"system":"sec-edgar","filing":"0001415889-25-005366","document":"form4-02242025_070201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036798/000141588925005366/form4-02242025_070201.xml","form_type":"4"}},{"id":1292045,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":64010,"kind":"person","name":"ALEXANDER MARGARET A.","position":1,"cik":"0002036798","reported_name":"ALEXANDER MARGARET A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2025-01-29T09:18:08.000Z","date":"2025-01-27","kind":"purchase","planned":false,"acquired":true,"shares":6810,"price":0.73,"value":4971.3,"ownership":{"direct":true},"balance_after":34935,"source":{"system":"sec-edgar","filing":"0001415889-25-002230","document":"form4-01292025_020104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036798/000141588925002230/form4-01292025_020104.xml","form_type":"4"}},{"id":1331030,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-16T21:15:20.000Z","date":"2024-12-12","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares will vest in 36 equal monthly installments, subject to the Reporting Person's continued services through such date."}],"balance_after":90000,"derivative":{"exercise_price":1.06,"expiration_date":"2034-12-11","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001415889-24-029474","document":"form4-12162024_041217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886431/000141588924029474/form4-12162024_041217.xml","form_type":"4"}},{"id":1330591,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53061,"kind":"person","name":"Friedman Bart","position":1,"cik":"0001368324","reported_name":"Friedman Bart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-16T21:15:19.000Z","date":"2024-12-12","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares will vest in 36 equal monthly installments, subject to the Reporting Person's continued services through such date."}],"balance_after":90000,"derivative":{"exercise_price":1.06,"expiration_date":"2034-12-11","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001415889-24-029473","document":"form4-12162024_041215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368324/000141588924029473/form4-12162024_041215.xml","form_type":"4"}},{"id":1330686,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-16T21:15:16.000Z","date":"2024-12-12","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares will vest in 36 equal monthly installments, subject to the Reporting Person's continued services through such date."}],"balance_after":90000,"derivative":{"exercise_price":1.06,"expiration_date":"2034-12-11","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001415889-24-029472","document":"form4-12162024_041213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000141588924029472/form4-12162024_041213.xml","form_type":"4"}},{"id":1330465,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63872,"kind":"person","name":"Bernstein Karen","position":1,"cik":"0001654055","reported_name":"Bernstein Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-16T21:15:15.000Z","date":"2024-12-12","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares will vest in 36 equal monthly installments, subject to the Reporting Person's continued services through such date."}],"balance_after":90000,"derivative":{"exercise_price":1.06,"expiration_date":"2034-12-11","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001415889-24-029471","document":"form4-12162024_041211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000141588924029471/form4-12162024_041211.xml","form_type":"4"}},{"id":1409997,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":64010,"kind":"person","name":"ALEXANDER MARGARET A.","position":1,"cik":"0002036798","reported_name":"ALEXANDER MARGARET A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-09-11T17:38:01.000Z","date":"2024-09-09","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on September 9, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date."}],"balance_after":140000,"derivative":{"exercise_price":1.07,"expiration_date":"2034-09-08","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001415889-24-023237","document":"form4-09112024_090958.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2036798/000141588924023237/form4-09112024_090958.xml","form_type":"4"}},{"id":1444176,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-08-01T21:00:06.000Z","date":"2024-07-30","kind":"grant","planned":false,"acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"50% of the shares subject to the option shall vest on July 30, 2025, and the remaining shares subject to the option shall vest in 12 equal monthly installments thereafter, subject to Reporting Person's continuous service on each such date."}],"balance_after":315000,"derivative":{"exercise_price":1.045,"expiration_date":"2034-07-29","underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0001415889-24-020526","document":"form4-08012024_050801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000141588924020526/form4-08012024_050801.xml","form_type":"4"}},{"id":1565793,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-03-20T21:22:00.000Z","date":"2024-03-18","kind":"purchase","planned":false,"acquired":true,"shares":18248,"price":2.76,"value":50364.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.76 to $2.78 inclusive. The reporting person undertakes to provide to Ovid Therapeutics Inc., any security holder of Ovid Therapeutics Inc., or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4."}],"balance_after":3616715,"source":{"system":"sec-edgar","filing":"0001209191-24-005001","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000120919124005001/doc4.xml","form_type":"4"}},{"id":1618588,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-26T23:05:11.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":168750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date."}],"balance_after":168750,"derivative":{"exercise_price":3.68,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":168750},"source":{"system":"sec-edgar","filing":"0001209191-24-003972","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919124003972/doc4.xml","form_type":"4"}},{"id":1618587,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-02-26T23:05:11.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":28125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (RSU) award. One-third (1/3) of the total number of RSUs shall vest on January 1, 2025 and one-third (1/3) of the remaining RSUs shall vest each year thereafter on anniversary of the vesting commencement date, subject to the Reporting Person's continuous service through such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":28125,"source":{"system":"sec-edgar","filing":"0001209191-24-003972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919124003972/doc4.xml","form_type":"4"}},{"id":1618928,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-26T23:03:53.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":168750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date."}],"balance_after":0,"derivative":{"exercise_price":3.68,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":168750},"source":{"system":"sec-edgar","filing":"0001209191-24-003970","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000120919124003970/doc4.xml","form_type":"4"}},{"id":1618927,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Common Stock","published_at":"2024-02-26T23:03:53.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":28125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (RSU) award. One-third (1/3) of the total number of RSUs shall vest on January 1, 2025 and one-third (1/3) of the remaining RSUs shall vest each year thereafter on anniversary of the vesting commencement date, subject to the Reporting Person's continuous service through such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":28125,"source":{"system":"sec-edgar","filing":"0001209191-24-003970","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000120919124003970/doc4.xml","form_type":"4"}},{"id":1618586,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":93876,"kind":"person","name":"Perone Thomas Michael","position":1,"cik":"0001771761","reported_name":"Perone Thomas Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-26T23:00:45.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":168750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date."}],"balance_after":168750,"derivative":{"exercise_price":3.68,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":168750},"source":{"system":"sec-edgar","filing":"0001209191-24-003966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919124003966/doc4.xml","form_type":"4"}},{"id":1618585,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":93876,"kind":"person","name":"Perone Thomas Michael","position":1,"cik":"0001771761","reported_name":"Perone Thomas Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Secretary"}}],"security":"Common Stock","published_at":"2024-02-26T23:00:45.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":28125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (RSU) award. One-third (1/3) of the total number of RSUs shall vest on January 1, 2025 and one-third (1/3) of the remaining RSUs shall vest each year thereafter on anniversary of the vesting commencement date, subject to the Reporting Person's continuous service through such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of Common Stock."}],"balance_after":28125,"source":{"system":"sec-edgar","filing":"0001209191-24-003966","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919124003966/doc4.xml","form_type":"4"}},{"id":1618939,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-26T22:58:39.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date."}],"balance_after":700000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0001209191-24-003964","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000120919124003964/doc4.xml","form_type":"4"}},{"id":1618867,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53061,"kind":"person","name":"Friedman Bart","position":1,"cik":"0001368324","reported_name":"Friedman Bart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-26T22:57:32.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 22, 2025, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-24-003962","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368324/000120919124003962/doc4.xml","form_type":"4"}},{"id":1619863,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-26T22:56:04.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 22, 2025, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-24-003960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886431/000120919124003960/doc4.xml","form_type":"4"}},{"id":1619053,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-26T22:54:34.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 22, 2025, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-24-003958","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919124003958/doc4.xml","form_type":"4"}},{"id":1618584,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63872,"kind":"person","name":"Bernstein Karen","position":1,"cik":"0001654055","reported_name":"Bernstein Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-26T22:53:07.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 22, 2025, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-24-003956","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919124003956/doc4.xml","form_type":"4"}},{"id":1619819,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":93907,"kind":"person","name":"Poole Robert Michael","position":1,"cik":"0001871782","reported_name":"Poole Robert Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-26T18:01:37.000Z","date":"2024-02-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 22, 2025, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":3.68,"expiration_date":"2034-02-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-24-003968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871782/000120919124003968/doc4.xml","form_type":"4"}},{"id":1642777,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-02-14T21:15:21.000Z","date":"2019-09-20","kind":"gift","planned":false,"acquired":false,"shares":465116,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were transferred to two family trusts for the benefit of the Reporting Person's adult children as part of generational estate planning. These transfers were made for no consideration. The Reporting Person does not serve as the trustee of the family trusts, nor does he maintain investment control over, or have a pecuniary interest in, the shares.  These transactions are being reported late due to an inadvertent administrative error."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Prior to the gift, the reportable securities were owned directly by DSL-EAL Holdings LLC (the \"LLC\"). The Reporting Person is the manager of the LLC. The Reporting Person may be deemed to share voting and investment powers for the shares held by the LLC. The Reporting Person disclaims beneficial ownership of the shares held by the LLC and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose, except to the extent of any pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-003721","document":"form4a-02142024_040202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000141588924003721/form4a-02142024_040202.xml","form_type":"4/A","original_submission_date":"2019-10-10"}},{"id":1719932,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-12-06T22:05:47.000Z","date":"2023-12-04","kind":"gift","planned":false,"acquired":false,"shares":573275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting executive has transferred shares to a family trust for the benefit of his children as part of generational estate planning. The\nreporting executive has made these transfers for no consideration. The reporting executive does not serve as the trustee of the family trusts, nor\ndoes he maintain investment control over, or have a pecuniary interest in, the shares."}],"balance_after":3598467,"source":{"system":"sec-edgar","filing":"0001209191-23-057640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000120919123057640/doc4.xml","form_type":"4"}},{"id":1719931,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2023-12-06T22:05:47.000Z","date":"2023-12-04","kind":"gift","planned":false,"acquired":false,"shares":573275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting executive has transferred shares to a family trust for the benefit of his children as part of generational estate planning. The\nreporting executive has made these transfers for no consideration. The reporting executive does not serve as the trustee of the family trusts, nor\ndoes he maintain investment control over, or have a pecuniary interest in, the shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This direct ownership total corrects an inadvertent administrative error in the number of shares of common stock that were reported as directly held on the Form 4 filed by the reporting executive on September 1, 2020. Before the transactions reported herein, the reporting executive held 4,745,017 shares of common stock directly"}],"balance_after":4171742,"source":{"system":"sec-edgar","filing":"0001209191-23-057640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000120919123057640/doc4.xml","form_type":"4"}},{"id":1989610,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-27T22:27:44.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2024 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date."}],"balance_after":175000,"derivative":{"exercise_price":2.5,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-23-013309","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919123013309/doc4.xml","form_type":"4"}},{"id":1989897,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-27T22:24:42.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2024 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date."}],"balance_after":175000,"derivative":{"exercise_price":2.5,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-23-013301","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000120919123013301/doc4.xml","form_type":"4"}},{"id":1989609,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":93876,"kind":"person","name":"Perone Thomas Michael","position":1,"cik":"0001771761","reported_name":"Perone Thomas Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-27T22:00:03.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2024 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date."}],"balance_after":175000,"derivative":{"exercise_price":2.5,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-23-013239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919123013239/doc4.xml","form_type":"4"}},{"id":1989904,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-27T21:58:29.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2024 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date."}],"balance_after":600000,"derivative":{"exercise_price":2.5,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001209191-23-013236","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000120919123013236/doc4.xml","form_type":"4"}},{"id":1989841,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53061,"kind":"person","name":"Friedman Bart","position":1,"cik":"0001368324","reported_name":"Friedman Bart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-27T21:55:52.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 23, 2024 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.5,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-013229","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368324/000120919123013229/doc4.xml","form_type":"4"}},{"id":1990663,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-27T21:51:18.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 23, 2024 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.5,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-013215","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886431/000120919123013215/doc4.xml","form_type":"4"}},{"id":1990047,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-27T21:47:09.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 23, 2024 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.5,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-013207","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919123013207/doc4.xml","form_type":"4"}},{"id":1989608,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63872,"kind":"person","name":"Bernstein Karen","position":1,"cik":"0001654055","reported_name":"Bernstein Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-27T21:44:55.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 23, 2024 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.5,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-013203","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919123013203/doc4.xml","form_type":"4"}},{"id":1990638,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":93907,"kind":"person","name":"Poole Robert Michael","position":1,"cik":"0001871782","reported_name":"Poole Robert Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-27T17:01:47.000Z","date":"2023-02-23","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 23, 2024 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.5,"expiration_date":"2033-02-22","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-013251","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871782/000120919123013251/doc4.xml","form_type":"4"}},{"id":2159108,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2022-09-14T20:58:34.000Z","date":"2022-09-12","kind":"sale","acquired":false,"shares":17344,"price":2.15,"value":37289.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person acquired the shares pursuant to the Issuer's employee stock purchase plan. These transactions were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Following the reported transaction, the Reporting Person will hold no ESPP shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person acquired the shares pursuant to the Issuer's employee stock purchase plan. These transactions were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Following the reported transaction, the Reporting Person will hold no ESPP shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-22-049938","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919122049938/doc4.xml","form_type":"4"}},{"id":2212063,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":2,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-07-06T06:28:15.000Z","date":"2022-07-01","kind":"other","acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the Restructuring, Millennium also distributed 1,250 shares of Ovid's Series A convertible preferred stock (the \"Preferred Stock\") to TPUSA. Each share of Preferred Stock is convertible into 1,000 shares of Common Stock at any time at the election of TPUSA, subject to a conversion cap that prevents TPUSA from converting the Preferred Stock if TPUSA or Takeda would beneficially own more than 14.99% of the total number of shares of Common Stock issued and outstanding following such conversion. TPUSA may elect to increase this conversion cap to up to 19.99% of the total number of shares of Common Stock by providing 61 days' written notice to the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the Restructuring, Millennium also distributed 1,250 shares of Ovid's Series A convertible preferred stock (the \"Preferred Stock\") to TPUSA. Each share of Preferred Stock is convertible into 1,000 shares of Common Stock at any time at the election of TPUSA, subject to a conversion cap that prevents TPUSA from converting the Preferred Stock if TPUSA or Takeda would beneficially own more than 14.99% of the total number of shares of Common Stock issued and outstanding following such conversion. TPUSA may elect to increase this conversion cap to up to 19.99% of the total number of shares of Common Stock by providing 61 days' written notice to the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Restructuring, Millennium also distributed 1,250 shares of Ovid's Series A convertible preferred stock (the \"Preferred Stock\") to TPUSA. Each share of Preferred Stock is convertible into 1,000 shares of Common Stock at any time at the election of TPUSA, subject to a conversion cap that prevents TPUSA from converting the Preferred Stock if TPUSA or Takeda would beneficially own more than 14.99% of the total number of shares of Common Stock issued and outstanding following such conversion. TPUSA may elect to increase this conversion cap to up to 19.99% of the total number of shares of Common Stock by providing 61 days' written notice to the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In connection with the Restructuring, Millennium also distributed 1,250 shares of Ovid's Series A convertible preferred stock (the \"Preferred Stock\") to TPUSA. Each share of Preferred Stock is convertible into 1,000 shares of Common Stock at any time at the election of TPUSA, subject to a conversion cap that prevents TPUSA from converting the Preferred Stock if TPUSA or Takeda would beneficially own more than 14.99% of the total number of shares of Common Stock issued and outstanding following such conversion. TPUSA may elect to increase this conversion cap to up to 19.99% of the total number of shares of Common Stock by providing 61 days' written notice to the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On July 1, 2022, the reporting persons effected an internal reorganization (the \"Restructuring\") whereby Millennium Pharmaceuticals, Inc. (\"Millennium\"), a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"), distributed its shares of Ovid Therapeutics Inc.'s (\"Ovid\") common stock (the \"Common Stock\") to TPUSA. TPUSA is a direct subsidiary of Takeda Pharmaceutical Company Limited (\"Takeda\") (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda. As such, Takeda is an indirect beneficial owner of the securities held by TPUSA, and its ownership remains unchanged from the Restructuring, including the 1,781,996 shares of Common Stock held directly by Takeda. No additional consideration was paid as part of the distribution of the Common Stock from Millennium to TPUSA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In connection with the Restructuring, Millennium also distributed 1,250 shares of Ovid's Series A convertible preferred stock (the \"Preferred Stock\") to TPUSA. Each share of Preferred Stock is convertible into 1,000 shares of Common Stock at any time at the election of TPUSA, subject to a conversion cap that prevents TPUSA from converting the Preferred Stock if TPUSA or Takeda would beneficially own more than 14.99% of the total number of shares of Common Stock issued and outstanding following such conversion. TPUSA may elect to increase this conversion cap to up to 19.99% of the total number of shares of Common Stock by providing 61 days' written notice to the issuer."}],"balance_after":1250,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0001395064-22-000121","document":"wf-form4_165710328185839.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1716229/000139506422000121/wf-form4_165710328185839.xml","form_type":"4"}},{"id":2212062,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":2,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-07-06T06:28:15.000Z","date":"2022-07-01","kind":"other","acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"In connection with the Restructuring, Millennium also distributed 1,250 shares of Ovid's Series A convertible preferred stock (the \"Preferred Stock\") to TPUSA. Each share of Preferred Stock is convertible into 1,000 shares of Common Stock at any time at the election of TPUSA, subject to a conversion cap that prevents TPUSA from converting the Preferred Stock if TPUSA or Takeda would beneficially own more than 14.99% of the total number of shares of Common Stock issued and outstanding following such conversion. TPUSA may elect to increase this conversion cap to up to 19.99% of the total number of shares of Common Stock by providing 61 days' written notice to the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the Restructuring, Millennium also distributed 1,250 shares of Ovid's Series A convertible preferred stock (the \"Preferred Stock\") to TPUSA. Each share of Preferred Stock is convertible into 1,000 shares of Common Stock at any time at the election of TPUSA, subject to a conversion cap that prevents TPUSA from converting the Preferred Stock if TPUSA or Takeda would beneficially own more than 14.99% of the total number of shares of Common Stock issued and outstanding following such conversion. TPUSA may elect to increase this conversion cap to up to 19.99% of the total number of shares of Common Stock by providing 61 days' written notice to the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the Restructuring, Millennium also distributed 1,250 shares of Ovid's Series A convertible preferred stock (the \"Preferred Stock\") to TPUSA. Each share of Preferred Stock is convertible into 1,000 shares of Common Stock at any time at the election of TPUSA, subject to a conversion cap that prevents TPUSA from converting the Preferred Stock if TPUSA or Takeda would beneficially own more than 14.99% of the total number of shares of Common Stock issued and outstanding following such conversion. TPUSA may elect to increase this conversion cap to up to 19.99% of the total number of shares of Common Stock by providing 61 days' written notice to the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In connection with the Restructuring, Millennium also distributed 1,250 shares of Ovid's Series A convertible preferred stock (the \"Preferred Stock\") to TPUSA. Each share of Preferred Stock is convertible into 1,000 shares of Common Stock at any time at the election of TPUSA, subject to a conversion cap that prevents TPUSA from converting the Preferred Stock if TPUSA or Takeda would beneficially own more than 14.99% of the total number of shares of Common Stock issued and outstanding following such conversion. TPUSA may elect to increase this conversion cap to up to 19.99% of the total number of shares of Common Stock by providing 61 days' written notice to the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On July 1, 2022, the reporting persons effected an internal reorganization (the \"Restructuring\") whereby Millennium Pharmaceuticals, Inc. (\"Millennium\"), a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"), distributed its shares of Ovid Therapeutics Inc.'s (\"Ovid\") common stock (the \"Common Stock\") to TPUSA. TPUSA is a direct subsidiary of Takeda Pharmaceutical Company Limited (\"Takeda\") (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda. As such, Takeda is an indirect beneficial owner of the securities held by TPUSA, and its ownership remains unchanged from the Restructuring, including the 1,781,996 shares of Common Stock held directly by Takeda. No additional consideration was paid as part of the distribution of the Common Stock from Millennium to TPUSA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"In connection with the Restructuring, Millennium also distributed 1,250 shares of Ovid's Series A convertible preferred stock (the \"Preferred Stock\") to TPUSA. Each share of Preferred Stock is convertible into 1,000 shares of Common Stock at any time at the election of TPUSA, subject to a conversion cap that prevents TPUSA from converting the Preferred Stock if TPUSA or Takeda would beneficially own more than 14.99% of the total number of shares of Common Stock issued and outstanding following such conversion. TPUSA may elect to increase this conversion cap to up to 19.99% of the total number of shares of Common Stock by providing 61 days' written notice to the issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0001395064-22-000121","document":"wf-form4_165710328185839.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1716229/000139506422000121/wf-form4_165710328185839.xml","form_type":"4"}},{"id":2212061,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":2,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-06T06:28:15.000Z","date":"2022-07-01","kind":"other","acquired":true,"shares":5750000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 1, 2022, the reporting persons effected an internal reorganization (the \"Restructuring\") whereby Millennium Pharmaceuticals, Inc. (\"Millennium\"), a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"), distributed its shares of Ovid Therapeutics Inc.'s (\"Ovid\") common stock (the \"Common Stock\") to TPUSA. TPUSA is a direct subsidiary of Takeda Pharmaceutical Company Limited (\"Takeda\") (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda. As such, Takeda is an indirect beneficial owner of the securities held by TPUSA, and its ownership remains unchanged from the Restructuring, including the 1,781,996 shares of Common Stock held directly by Takeda. No additional consideration was paid as part of the distribution of the Common Stock from Millennium to TPUSA."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 1, 2022, the reporting persons effected an internal reorganization (the \"Restructuring\") whereby Millennium Pharmaceuticals, Inc. (\"Millennium\"), a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"), distributed its shares of Ovid Therapeutics Inc.'s (\"Ovid\") common stock (the \"Common Stock\") to TPUSA. TPUSA is a direct subsidiary of Takeda Pharmaceutical Company Limited (\"Takeda\") (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda. As such, Takeda is an indirect beneficial owner of the securities held by TPUSA, and its ownership remains unchanged from the Restructuring, including the 1,781,996 shares of Common Stock held directly by Takeda. No additional consideration was paid as part of the distribution of the Common Stock from Millennium to TPUSA."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On July 1, 2022, the reporting persons effected an internal reorganization (the \"Restructuring\") whereby Millennium Pharmaceuticals, Inc. (\"Millennium\"), a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"), distributed its shares of Ovid Therapeutics Inc.'s (\"Ovid\") common stock (the \"Common Stock\") to TPUSA. TPUSA is a direct subsidiary of Takeda Pharmaceutical Company Limited (\"Takeda\") (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda. As such, Takeda is an indirect beneficial owner of the securities held by TPUSA, and its ownership remains unchanged from the Restructuring, including the 1,781,996 shares of Common Stock held directly by Takeda. No additional consideration was paid as part of the distribution of the Common Stock from Millennium to TPUSA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On July 1, 2022, the reporting persons effected an internal reorganization (the \"Restructuring\") whereby Millennium Pharmaceuticals, Inc. (\"Millennium\"), a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"), distributed its shares of Ovid Therapeutics Inc.'s (\"Ovid\") common stock (the \"Common Stock\") to TPUSA. TPUSA is a direct subsidiary of Takeda Pharmaceutical Company Limited (\"Takeda\") (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda. As such, Takeda is an indirect beneficial owner of the securities held by TPUSA, and its ownership remains unchanged from the Restructuring, including the 1,781,996 shares of Common Stock held directly by Takeda. No additional consideration was paid as part of the distribution of the Common Stock from Millennium to TPUSA."}],"balance_after":5750000,"source":{"system":"sec-edgar","filing":"0001395064-22-000121","document":"wf-form4_165710328185839.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716229/000139506422000121/wf-form4_165710328185839.xml","form_type":"4"}},{"id":2212060,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK","position":1,"cik":"0001395064","reported_name":"TAKEDA PHARMACEUTICAL CO LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71983,"kind":"organization","name":"Takeda Pharmaceuticals U.S.A., Inc.","position":2,"cik":"0001716229","reported_name":"Takeda Pharmaceuticals U.S.A., Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-07-06T06:28:15.000Z","date":"2022-07-01","kind":"other","acquired":false,"shares":5750000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 1, 2022, the reporting persons effected an internal reorganization (the \"Restructuring\") whereby Millennium Pharmaceuticals, Inc. (\"Millennium\"), a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"), distributed its shares of Ovid Therapeutics Inc.'s (\"Ovid\") common stock (the \"Common Stock\") to TPUSA. TPUSA is a direct subsidiary of Takeda Pharmaceutical Company Limited (\"Takeda\") (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda. As such, Takeda is an indirect beneficial owner of the securities held by TPUSA, and its ownership remains unchanged from the Restructuring, including the 1,781,996 shares of Common Stock held directly by Takeda. No additional consideration was paid as part of the distribution of the Common Stock from Millennium to TPUSA."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 1, 2022, the reporting persons effected an internal reorganization (the \"Restructuring\") whereby Millennium Pharmaceuticals, Inc. (\"Millennium\"), a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"), distributed its shares of Ovid Therapeutics Inc.'s (\"Ovid\") common stock (the \"Common Stock\") to TPUSA. TPUSA is a direct subsidiary of Takeda Pharmaceutical Company Limited (\"Takeda\") (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda. As such, Takeda is an indirect beneficial owner of the securities held by TPUSA, and its ownership remains unchanged from the Restructuring, including the 1,781,996 shares of Common Stock held directly by Takeda. No additional consideration was paid as part of the distribution of the Common Stock from Millennium to TPUSA."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"On July 1, 2022, the reporting persons effected an internal reorganization (the \"Restructuring\") whereby Millennium Pharmaceuticals, Inc. (\"Millennium\"), a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"), distributed its shares of Ovid Therapeutics Inc.'s (\"Ovid\") common stock (the \"Common Stock\") to TPUSA. TPUSA is a direct subsidiary of Takeda Pharmaceutical Company Limited (\"Takeda\") (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda. As such, Takeda is an indirect beneficial owner of the securities held by TPUSA, and its ownership remains unchanged from the Restructuring, including the 1,781,996 shares of Common Stock held directly by Takeda. No additional consideration was paid as part of the distribution of the Common Stock from Millennium to TPUSA."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On July 1, 2022, the reporting persons effected an internal reorganization (the \"Restructuring\") whereby Millennium Pharmaceuticals, Inc. (\"Millennium\"), a wholly owned subsidiary of Takeda Pharmaceuticals U.S.A., Inc. (\"TPUSA\"), distributed its shares of Ovid Therapeutics Inc.'s (\"Ovid\") common stock (the \"Common Stock\") to TPUSA. TPUSA is a direct subsidiary of Takeda Pharmaceutical Company Limited (\"Takeda\") (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda. As such, Takeda is an indirect beneficial owner of the securities held by TPUSA, and its ownership remains unchanged from the Restructuring, including the 1,781,996 shares of Common Stock held directly by Takeda. No additional consideration was paid as part of the distribution of the Common Stock from Millennium to TPUSA."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001395064-22-000121","document":"wf-form4_165710328185839.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716229/000139506422000121/wf-form4_165710328185839.xml","form_type":"4"}},{"id":2298253,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53061,"kind":"person","name":"Friedman Bart","position":1,"cik":"0001368324","reported_name":"Friedman Bart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-12T21:53:40.000Z","date":"2022-04-08","kind":"grant","acquired":true,"shares":69424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":69424,"derivative":{"exercise_price":3.22,"expiration_date":"2032-04-07","underlying":"Common Stock","underlying_shares":69424},"source":{"system":"sec-edgar","filing":"0001209191-22-024198","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368324/000120919122024198/doc4.xml","form_type":"4"}},{"id":2298185,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-12T21:40:44.000Z","date":"2022-04-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable on April 8, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous services through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":3.22,"expiration_date":"2023-04-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-024191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919122024191/doc4.xml","form_type":"4"}},{"id":2298184,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-12T21:40:44.000Z","date":"2022-04-08","kind":"grant","acquired":true,"shares":87498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":87498,"derivative":{"exercise_price":3.22,"expiration_date":"2023-04-07","underlying":"Common Stock","underlying_shares":87498},"source":{"system":"sec-edgar","filing":"0001209191-22-024191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919122024191/doc4.xml","form_type":"4"}},{"id":2298274,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-12T21:36:41.000Z","date":"2022-04-08","kind":"grant","acquired":true,"shares":423244,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":423244,"derivative":{"exercise_price":3.22,"expiration_date":"2032-04-07","underlying":"Common Stock","underlying_shares":423244},"source":{"system":"sec-edgar","filing":"0001209191-22-024189","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000120919122024189/doc4.xml","form_type":"4"}},{"id":2298273,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-12T21:34:36.000Z","date":"2022-04-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable on April 8, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous services through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":3.22,"expiration_date":"2032-04-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-024187","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000120919122024187/doc4.xml","form_type":"4"}},{"id":2298272,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-12T21:34:36.000Z","date":"2022-04-08","kind":"grant","acquired":true,"shares":194399,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable on October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":194399,"derivative":{"exercise_price":3.22,"expiration_date":"2032-04-07","underlying":"Common Stock","underlying_shares":194399},"source":{"system":"sec-edgar","filing":"0001209191-22-024187","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000120919122024187/doc4.xml","form_type":"4"}},{"id":2298183,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":93876,"kind":"person","name":"Perone Thomas Michael","position":1,"cik":"0001771761","reported_name":"Perone Thomas Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-12T21:30:42.000Z","date":"2022-04-08","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable on April 8, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous services through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":3.22,"expiration_date":"2032-04-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-024185","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919122024185/doc4.xml","form_type":"4"}},{"id":2298182,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":93876,"kind":"person","name":"Perone Thomas Michael","position":1,"cik":"0001771761","reported_name":"Perone Thomas Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-12T21:30:42.000Z","date":"2022-04-08","kind":"grant","acquired":true,"shares":25399,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":25399,"derivative":{"exercise_price":3.22,"expiration_date":"2032-04-07","underlying":"Common Stock","underlying_shares":25399},"source":{"system":"sec-edgar","filing":"0001209191-22-024185","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919122024185/doc4.xml","form_type":"4"}},{"id":2298296,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-12T20:55:36.000Z","date":"2022-04-08","kind":"grant","acquired":true,"shares":21347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":21347,"derivative":{"exercise_price":3.22,"expiration_date":"2032-04-07","underlying":"Common Stock","underlying_shares":21347},"source":{"system":"sec-edgar","filing":"0001209191-22-024163","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919122024163/doc4.xml","form_type":"4"}},{"id":2298180,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63872,"kind":"person","name":"Bernstein Karen","position":1,"cik":"0001654055","reported_name":"Bernstein Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-12T20:44:23.000Z","date":"2022-04-08","kind":"grant","acquired":true,"shares":69424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":69424,"derivative":{"exercise_price":3.22,"expiration_date":"2032-04-07","underlying":"Common Stock","underlying_shares":69424},"source":{"system":"sec-edgar","filing":"0001209191-22-024159","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919122024159/doc4.xml","form_type":"4"}},{"id":2411457,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53061,"kind":"person","name":"Friedman Bart","position":1,"cik":"0001368324","reported_name":"Friedman Bart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-05T01:50:34.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 3, 2023 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.72,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-007328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1368324/000120919122007328/doc4.xml","form_type":"4"}},{"id":2411857,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-05T01:49:33.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 3, 2023 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.72,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-007327","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886431/000120919122007327/doc4.xml","form_type":"4"}},{"id":2411554,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":35951,"kind":"person","name":"DUNCAN BARBARA GAYLE","position":1,"cik":"0001353128","reported_name":"Duncan Barbara Gayle","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-05T01:48:56.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 3, 2023 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.72,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-007326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353128/000120919122007326/doc4.xml","form_type":"4"}},{"id":2411323,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63872,"kind":"person","name":"Bernstein Karen","position":1,"cik":"0001654055","reported_name":"Bernstein Karen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-05T01:47:33.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 3, 2023 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.72,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-007325","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919122007325/doc4.xml","form_type":"4"}},{"id":2411321,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-04T23:24:13.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 3, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date."}],"balance_after":175000,"derivative":{"exercise_price":2.72,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-22-007314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919122007314/doc4.xml","form_type":"4"}},{"id":2411473,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":63894,"kind":"person","name":"Rona Jeffrey A","position":1,"cik":"0001311404","reported_name":"Rona Jeffrey A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CBFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-04T23:22:18.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":218750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 3, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date."}],"balance_after":218750,"derivative":{"exercise_price":2.72,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":218750},"source":{"system":"sec-edgar","filing":"0001209191-22-007311","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311404/000120919122007311/doc4.xml","form_type":"4"}},{"id":2411322,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":93876,"kind":"person","name":"Perone Thomas Michael","position":1,"cik":"0001771761","reported_name":"Perone Thomas Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel, Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-04T23:19:49.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 3, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date."}],"balance_after":175000,"derivative":{"exercise_price":2.72,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001209191-22-007310","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919122007310/doc4.xml","form_type":"4"}},{"id":2411476,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":16837,"kind":"person","name":"LEVIN JEREMY M","position":1,"cik":"0001256153","reported_name":"LEVIN JEREMY M","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-04T23:14:17.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on February 3, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date."}],"balance_after":600000,"derivative":{"exercise_price":2.72,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001209191-22-007305","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1256153/000120919122007305/doc4.xml","form_type":"4"}},{"id":2411852,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":93907,"kind":"person","name":"Poole Robert Michael","position":1,"cik":"0001871782","reported_name":"Poole Robert Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-04T20:51:56.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on February 3, 2023 subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.72,"expiration_date":"2032-02-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-007329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871782/000120919122007329/doc4.xml","form_type":"4"}},{"id":2546539,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":53095,"kind":"person","name":"Fitzgerald Kevin Joseph","position":1,"cik":"0001886431","reported_name":"Fitzgerald Kevin Joseph","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-07T20:44:08.000Z","date":"2021-10-06","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as follows: 1/36th of the shares subject to the option shall vest every month after October 6, 2021 such that the option will have vested in full on October 6, 2024, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2017 Equity Incentive Plan) on each vesting date."}],"balance_after":30000,"derivative":{"exercise_price":3.44,"expiration_date":"2031-10-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-059940","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886431/000120919121059940/doc4.xml","form_type":"4"}},{"id":2631593,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":137270,"kind":"person","name":"Rakhit Amit","position":1,"cik":"0001704636","reported_name":"Rakhit Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-16T22:21:39.000Z","date":"2021-07-14","kind":"exercise","acquired":true,"shares":34017,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the Stock Options vested and become exercisable on February 24, 2020 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date."}],"balance_after":90983,"derivative":{"exercise_price":1.89,"expiration_date":"2029-02-23","underlying":"Common Stock","underlying_shares":34017},"source":{"system":"sec-edgar","filing":"0001209191-21-046995","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919121046995/doc4.xml","form_type":"4"}},{"id":2631592,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":137270,"kind":"person","name":"Rakhit Amit","position":1,"cik":"0001704636","reported_name":"Rakhit Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CMO"}}],"security":"Common Stock","published_at":"2021-07-16T22:21:39.000Z","date":"2021-07-14","kind":"sale","acquired":false,"shares":34017,"price":3.71,"value":126203.07,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.70 to $3.745, inclusive. The reporting person undertakes to provide to Ovid Therapeutics Inc, any security holder of Ovid Therapeutics Inc, or staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4"}],"balance_after":726823,"source":{"system":"sec-edgar","filing":"0001209191-21-046995","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919121046995/doc4.xml","form_type":"4"}},{"id":2631591,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":137270,"kind":"person","name":"Rakhit Amit","position":1,"cik":"0001704636","reported_name":"Rakhit Amit","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CMO"}}],"security":"Common Stock","published_at":"2021-07-16T22:21:39.000Z","date":"2021-07-14","kind":"exercise","acquired":true,"shares":34017,"price":1.89,"value":64292.13,"ownership":{"direct":true},"balance_after":760840,"source":{"system":"sec-edgar","filing":"0001209191-21-046995","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919121046995/doc4.xml","form_type":"4"}},{"id":2635036,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":93907,"kind":"person","name":"Poole Robert Michael","position":1,"cik":"0001871782","reported_name":"Poole Robert Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-13T16:25:15.000Z","date":"2021-07-09","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as follows: 1/36th of the shares subject to the option shall vest every month after July 9, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2017 Equity Incentive Plan) on each vesting date."}],"balance_after":30000,"derivative":{"exercise_price":3.94,"expiration_date":"2031-07-08","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-046497","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1871782/000120919121046497/doc4.xml","form_type":"4"}},{"id":2647095,"issuer":{"id":5411,"kind":"organization","name":"Ovid Therapeutics Inc."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-01T20:23:36.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on July 1, 2022 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date."}],"balance_after":50000,"derivative":{"exercise_price":3.95,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-044391","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636651/000120919121044391/doc4.xml","form_type":"4"}}],"next_cursor":"2021-07-01T20:23:36.000000Z,2647095"}